natgillin/translations-raw huggingface dataset:
Other side effects Tell your doctor, pharmacist or nurse if you notice any of the following side effects:
Obavijestite liječnika, ljekarnika ili medicinsku sestru ako primijetite neku od sljedećih nuspojava:
Posaconazole is excreted into the milk of lactating rats (see section 5.3).
Dojenje Posakonazol se izlučuje u mlijeko ženki štakora tijekom laktacije (vidjeti dio 5.3).
Steady-state is attained following 7 to 10 days of multiple-dose administration.
Stanje dinamičke ravnoteže postiže se nakon 7 do 10 dana primjene ponovljenih doza.
Do not take Posaconazole AHCL - if you are allergic to posaconazole or any of the other ingredients of this medicine (listed in section 6).
• ako ste alergični na posakonazol ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
- if you are taking: terfenadine, astemizole, cisapride, pimozide, halofantrine, quinidine, any medicines that contain “ergot alkaloids” such as ergotamine or dihydroergotamine, or a “statin” such as simvastatin, atorvastatin or lovastatin
• ako uzimate terfenadin, astemizol, cisaprid, pimozid, halofantrin, kinidin, bilo koji lijek koji sadrži ergot alkaloide kao što su ergotamin ili dihidroergotamin ili statine kao što su simvastatin, atorvastatin ili lovastatin.
Rifabutin (300 mg once a day) decreased the Cmax (maximum plasma concentration) and AUC (area under the plasma concentration time curve) of posaconazole to 57 % and 51 %, respectively.
Rifabutin (300 mg jedanput na dan) je snizio Cmax (maksimalna koncentracija u plazmi) posakonazola na 57%, a AUC (površina ispod krivulje koncentracija u plazmi-vrijeme) na 51%.
- bleeding into your stomach or gut - signs include vomiting blood or passing blood in your stool - a blockage in your gut (intestinal obstruction) especially in the “ileum”.
- krvarenje u želudac ili crijeva - znakovi uključuju povraćanje krvi ili krv u stolici - blokada crijeva (opstrukcija crijeva), osobito završnog dijela tankog crijeva (ileum).
- some medicines used to treat or prevent fits including; phenytoin, carbamazepine, phenobarbital or primidone).
- neki lijekovi koji se primjenjuju u liječenju ili sprječavanju napadaja, uključujući fenitoin, karbamazepin, fenobarbital ili primidon.
Pharmacokinetic modeling with an oral tablet formulation suggests that patients weighing greater than 120 kg may have lower posaconazole exposure.
Farmakokinetičko modeliranje provedeno s lijekom u obliku tableta za peroralnu primjenu upućuje na to da bi izloženost posakonazolu mogla biti manja u bolesnika tjelesne težine veće od 120 kg.
Following single-dose administration of posaconazole oral suspension, there was no effect of mild and moderate renal impairment (n=18, Cl cr ≥ 20 mL/min/1.73 m2) on posaconazole pharmacokinetics; therefore, no dose adjustment is required.
Nakon primjene jednokratne doze posakonazol oralne suspenzije, blago ili umjereno oštećenje funkcije bubrega (n=18, CIcr ≥ 20 ml/min/1,73 m2) nije utjecalo na farmakokinetiku posakonazola, pa nije potrebna prilagodba doze.
Co-administration of posaconazole with proton pump inhibitors should be avoided if possible.
Ako je moguće, istodobnu primjenu posakonazola i inhibitora protonske pumpe potrebno je izbjegavati.
The primary packaging is an amber glass bottle (Type III) closed with a child-resistant and tamper evident polypropylene cap.
Unutarnje pakiranje je smeđa (jantarna) staklena boca (tip III) zatvorena zatvaračem sigurnim za djecu i zaštitnom polipropilenskom kapicom s evidencijom otvaranja.
Concomitant use of posaconazole and rifabutin should be avoided unless the benefit to the patient outweighs the risk (see also above regarding the effect of rifabutin on plasma levels of posaconazole).
Istodobnu primjenu posakonazola i rifabutina potrebno je izbjegavati, osim ako moguća korist za bolesnika nadilazi rizik liječenja (o učinku rifabutina na koncentraciju posakonazola u plazmi vidjeti također u gornjem tekstu).
Do not take Posaconazole AHCL if you are taking any of the following: - terfenadine (used to treat allergies) - astemizole (used to treat allergies) - cisapride (used to treat stomach problems) - pimozide (used to treat symptoms of Tourette's and mental illness) - halofantrine (used to treat malaria) - quinidine (used to treat abnormal heart rhythms).
Nemojte uzimati Posakonazol AHCL ako uzimate neki od sljedećih lijekova: - terfenadin (primjenjuje se za liječenje alergija); - astemizol (primjenjuje se za liječenje alergija); - cisaprid (primjenjuje se za liječenje želučanih tegoba); - pimozid (primjenjuje se za liječenje simptoma Touretteovog sindroma i duševne bolesti); - halofantrin (primjenjuje se za liječenje malarije); - kinidin (primjenjuje se za liječenje poremećaja srčanog ritma).
The clinical response rates from the above study are shown in the Table 4 below.
Stope kliničkog odgovora u ovom ispitivanju prikazane su u Tablici
If you take more Posaconazole AHCL than you should If you are concerned that you may have taken too much, contact your doctor or healthcare professional immediately.
Ako uzmete više lijeka Posakonazol AHCL nego što ste trebali Ako mislite da ste uzeli previše lijeka Posakonazol AHCL, odmah se obratite liječniku ili drugom zdravstvenom radniku.
If you develop severe diarrhoea or vomiting (being sick) while taking Posaconazole AHCL, talk to your doctor, pharmacist or nurse straight away, as this may stop it from working properly.
Ako dobijete teški proljev ili povraćate dok uzimate Posakonazol AHCL, odmah se obratite svom liječniku, ljekarniku ili medicinskoj sestri, jer to može narušiti ispravno djelovanje Posakonazol AHCLa.
Posaconazole AHCL must not be administered with medicinal products that are substrates for CYP3A4 and are known to prolong the QTc interval (see sections 4.3 and 4.5).
Posakonazol AHCL ne smije se primjenjivati s lijekovima koji su supstrati enzima CYP3A4 i za koje je poznato da produljuju QTcinterval (vidjeti dijelove 4.3 i 4.5).
Controla Proportion (%) of patients with proven/probable Aspergillosis On-treatment periodb
Posakonazol oralna suspenzija Kontrolna skupinaa Udio (%) bolesnika s dokazanom/vjerojatnom aspergilozom
You may feel dizzy, sleepy, or have blurred vision while taking Posaconazole AHCL, which may affect your ability to drive or use tools or machines.
Dok uzimate Posakonazol AHCL, možete osjetiti omaglicu, pospanost ili imati zamućen vid, što može utjecati na Vašu sposobnost upravljanja vozilima i rada sa strojevima.
Following administration of 800 mg per day of posaconazole as a divided dose for treatment of invasive fungal infections, mean trough plasma concentrations from 12 patients 8 - 17 years of age (776 ng/mL) were similar to concentrations from 194 patients 18 - 64 years of age (817 ng/mL).
Nakon primjene 800 mg posakonazola na dan, raspodijeljeno u više doza, za liječenje invazivnih gljivičnih infekcija srednja vrijednost najnižih koncentracija posakonazola u plazmi 12 bolesnika u dobi 8-17 godina (776 ng/ml) bila je slična onoj u 194 bolesnika u dobi 18-64 godina (817 ng/ml).
If you become pregnant while you are taking Posaconazole AHCL, contact your doctor straight away.
Ako zatrudnite tijekom liječenja lijekom Posakonazol AHCL, odmah se obratite svom liječniku.
Posaconazole may increase the plasma concentration of ergot alkaloids (ergotamine and dihydroergotamine), which may lead to ergotism.
Posakonazol može povećati koncentraciju ergot alkaloida (ergotamina i dihidroergotamina) u plazmi,
c: In 1899, this was the period from randomization to 100 days post-randomization; in 316 it was the period from the baseline day to 111 days post-baseline.
Ispitivanju 1899 to je bilo razdoblje od randomizacije do 100 dana nakon randomizacije; u ispitivanju 316 to je bilo razdoblje od dana početka ispitivanja do 111. dana nakon toga.
After a single oral dose of 400 mg posaconazole oral suspension to patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment (six per group), the mean AUC was 1.3 to 1.6-fold higher compared to that for matched control subjects with normal hepatic function.
Nakon jednokratne doze od 400 mg posakonazol oralne suspenzije u bolesnika s blagim (Child-Pugh stadij A), umjerenim (Child-Pugh stadij B) ili teškim oštećenjem funkcije jetre (Child-Pugh stadij C) (6 po grupi), srednja vrijednost AUC bila je 1,3 do 1,6 puta veća u odnosu na odgovarajuće ispitanike iz kontrolne skupine s normalnom funkcijom jetre.
Some patients have also reported feeling confused after taking Posaconazole AHCL, the frequency of this is not known.
Neki su bolesnici prijavili da su se nakon uzimanja lijeka Posakonazol AHCL osjećali smeteno, no učestalost ove nuspojave nije poznata.
Patients who develop abnormal liver function tests during Posaconazole AHCLtherapy must be routinely monitored for the development of more severe hepatic injury.
Bolesnike u kojih tijekom liječenja lijekom Posakonazol AHCL dođe do odstupanja od normalnih vrijednosti pretraga funkcije jetre mora se rutinski nadzirati zbog mogućeg razvoja težeg oštećenja jetre.
Posaconazole had no effect on fertility of male rats at doses up to 180 mg/kg (1.7 times the 400 mg twice daily regimen based on steady-state plasma concentrations in healthy volunteers) or female rats at a dose up to 45 mg/kg (2.2 times the 400-mg twice daily regimen).
Plodnost U štakora, posakonazol nije imao utjecaja na plodnost mužjaka pri dozama do najviše 180 mg/kg (što je 1,7 puta više od režima doziranja 400 mg dvaput na dan, izračunato na temelju koncentracije u plazmi u stanju dinamičke ravnoteže u zdravih dobrovoljaca) niti na plodnost ženki pri dozi do najviše 45 mg/kg (što je 2,2 puta više od režima doziranja 400 mg dvaput na dan).
Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients: - Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections; - Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.
Posakonazol AHCL oralna suspenzija indicirana je i za profilaksu invazivnih gljivičnih infekcija u sljedećih bolesnika: u bolesnika s akutnom mijeloičnom leukemijom (AML) ili mijelodisplastičnim sindromima (MDS) koji primaju kemoterapiju za postizanje remisije bolesti za koju se očekuje da će izazvati dugotrajnu neutropeniju i u kojih postoji velik rizik za razvoj invazivnih gljivičnih infekcija; u primatelja transplantiranih hematopoetskih matičnih stanica koji primaju visoke doze imunosupresiva zbog reakcije presatka protiv primatelja i u kojih postoji velik rizik za razvoj invazivnih gljivičnih infekcija.
Clinical success rate at Day 14 Clinical success rate 4 weeks after end of treatment
Postotak kliničkog uspjeha 14. dana liječenja
FLU = fluconazole; ITZ = itraconazole; POS = posaconazole.
FLU=flukonazol; ITZ=itrakonazol; POS=posakonazol a:
Alternatively, if recommended by your doctor, you may take 400 mg (two 5 mL spoonfuls) twice a day provided that you are able to take both doses during or after food or a nutritional drink.
400 mg (dvije žličice od 5 ml) dvaput na dan, pod uvjetom da obje doze možete uzeti tijekom ili nakon obroka ili nutritivnog napitka.
Posaconazole AHCL contains glucose
Posakonazol AHCL sadrži glukozu
renal tubular acidosis, interstitial nephritis Reproductive system and breast disorders Uncommon:
renalna tubularna acidoza, intersticijski nefritis Poremećaji reproduktivnog sustava i dojki
The AUC of posaconazole is: 4 times greater when administered with a high fat meal (~ 50 grams fat) and about 2.6 times greater when administered during a non-fat meal or nutritional supplement (14 grams fat) relative to the fasted state (see sections 4.2 and 4.5).
AUC posakonazola je 4 puta veći kad se primjenjuje uz obrok bogat mastima (~50 g masti) te približno 2,6 puta veći kad se primjenjuje uz nemasni obrok ili nadomjestak prehrani (14 g masti) u odnosu na primjenu na prazan želudac (vidjeti dijelove 4.2 i 4.5).
Posaconazole concentrations may be significantly lowered in combination; therefore, concomitant use with posaconazole should be avoided unless the benefit to the patient outweighs the risk (see section
Koncentracija posakonazola može biti značajno snižena u kombinaciji s ovim lijekovima pa istodobnu primjenu treba izbjegavati, osim ako moguća korist za bolesnika nadilazi rizik liječenja (vidjeti dio
Similarly, administration of 400 mg posaconazole with esomeprazole (40 mg daily) decreased mean Cmax and AUC by 46 % and 32 %, respectively, compared to dosing with 400 mg posaconazole alone.
Slično tomu, primjena 400 mg posakonazola s esomeprazolom (40 mg na dan) snizila je srednju vrijednost Cmax za 46%, a AUC za 32% u usporedbi s primjenom samog posakonazola u dozi od 400 mg.
The absorption of posaconazole was significantly increased when posaconazole 400 mg (once daily) was administered during and immediately after the consumption of a high fat meal (~ 50 grams fat) compared to administration before a meal, with Cmax and AUC increasing by approximately 330 % and 360 %, respectively.
Apsorpcija posakonazola značajno se povećala kad je posakonazol u dozi od 400 mg (jedanput na dan) primijenjen tijekom ili neposredno nakon obroka s visokim udjelom masti (~ 50 grama masti) u usporedbi s primjenom prije jela, uz povećanje Cmax za približno 330%, a AUC-a za približno 360%.
Concomitant use of posaconazole and rifabutin and similar inducers (e.g. rifampicin) should be avoided unless the benefit to the patient outweighs the risk.
Istodobnu primjenu posakonazola i rifabutina kao i sličnih induktora (npr. rifampicina) treba izbjegavati, osim ako moguća korist za bolesnika nadilazi rizik liječenja.
This medicine can also be used to prevent fungal infections in adults who are at high risk of getting a fungal infection, such as: - patients who have a weak immune system due to having chemotherapy for “acute myelogenous leukemia” (AML) or “myelodysplastic syndromes” (MDS) - patients having “high- dose immunosuppressive therapy” after “hematopoietic stem cell transplant” (HSCT).
Ovaj se lijek također može primjenjivati za sprječavanje gljivičnih infekcija u odraslih bolesnika s visokim rizikom od dobivanja gljivične infekcije, kao što su: - bolesnici čiji je imunološki sustav oslabljen zbog kemoterapije koju primaju za liječenje akutne mijeloične leukemije (AML) ili mijelodisplastičnog sindroma (MDS)
Posaconazole AHCL may possibly increase the risk of side effects of some other medicines by increasing the amount of these medicines in the blood.
Posakonazol AHCL može povećati rizik od nuspojava nekih drugih lijekova jer može povećati količinu tih lijekova u krvi.
Do not breast-feed while taking Posaconazole AHCL.
Nemojte dojiti dok uzimate Posakonazol AHCL.
If you have missed a dose, take it as soon as you remember and then carry on as before.
Ako ste zaboravili uzeti dozu, uzmite ju čim se sjetite i zatim nastavite uzimati Posakonazol AHCL
- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.
kandidijaze usta i ždrijela, kao prva linija liječenja bolesnika s teškim oblikom bolesti ili imunokompromitiranih bolesnika u kojih se očekuje slab odgovor na topikalnu terapiju.
What you need to know before you take Posaconazole AHCL
Što morate znati prije nego počnete uzimati Posakonazol AHCL
Neuronal phospholipidosis occurred in dogs dosed for ≥ 3 months at lower systemic exposures than those obtained at therapeutic doses in humans.
U pasa koji su primali lijek 3 mjeseca razvila se neuronska fosfolipidoza pri manjoj sistemskoj izloženosti od one koja se postiže s terapijskim dozama u ljudi.
altered medicine levels, blood phosphorus decreased, chest x-ray abnormal * Based on adverse reactions observed with the oral suspension, gastro-resistant tablets, and concentrate for solution for infusion.
odstupanja u rendgenskom nalazu prsnog koša * Na temelju nuspojava primijećenih kod primjene oralne suspenzije, želučanootpornih tableta i koncentrata za otopinu za infuziju.
Tell your doctor, pharmacist or nurse straight away if you notice any of the following serious side effects - you may need urgent medical treatment: - nausea or vomit (feeling or being sick), diarrhoea - signs of liver problems - these include yellowing of your skin or whites of the eyes, unusually dark urine or pale faeces, feeling sick for no reason, stomach problems, loss of appetite or unusual tiredness or weakness, an increase in liver enzymes shown up in blood tests - allergic reaction.
Odmah obavijestite liječnika, ljekarnika ili medicinsku sestru ako se pojavi neka od sljedećih ozbiljnih nuspojava - možda će Vam biti potrebno hitno liječenje: - mučnina ili povraćanje, proljev - znakovi tegoba s jetrom - oni uključuju žutu boju kože ili bjeloočnica, neobično tamnu boju mokraće ili svijetlu boju stolice, mučninu bez razloga, tegobe sa želucem, gubitak apetita ili neobičan umor ili slabost, povećanje vrijednosti jetrenih enzima na krvnim pretragama
Posaconazole AHCL can be used in adults to treat the following types of fungal infections when other antifungal medicines have not worked or you have had to stop taking them: - infections caused by fungi of the Aspergillus family that have not improved during treatment with the anti-fungal medicines amphotericin B or itraconazole or when these medicines have had to be stopped; - infections caused by fungi of the Fusarium family that have not improved during treatment with amphotericin B or when amphotericin B has had to be stopped; - infections caused by fungi that cause the conditions known as “chromoblastomycosis” and “mycetoma” that have not improved during treatment with itraconazole or when itraconazole has had to be stopped; - infections caused by a fungus called Coccidioides that have not improved during treatment with one or more of amphotericin B, itraconazole or fluconazole or when these medicines have had to be stopped.
- infekcija prouzročenih gljivicama iz roda Aspergillus koje se nisu poboljšale tijekom liječenja antimikoticima amfotericinom B ili itrakonazolom, ili kada se liječenje tim lijekovima moralo prekinuti; - infekcija prouzročenih gljivicama iz roda Fusarium koje se nisu poboljšale tijekom liječenja amfotericinom B, ili kada se liječenje amfotericinom B moralo prekinuti; - infekcija prouzročenih gljivicama koje uzrokuju bolesti kromoblastomikozu i micetom, a koje se nisu poboljšale tijekom liječenja itrakonazolom, ili kada se liječenje itrakonazolom moralo prekinuti;
Posaconazole AHCL 40 mg/mL oral suspension posaconazole
Posakonazol AHCL 40 mg/ml oralna suspenzija posakonazol
Echocardiography revealed no indication of cardiac decompensation in a repeat dose safety pharmacology study in rats at a systemic exposure 1.4-fold greater than that achieved therapeutically.
U farmakološkom ispitivanju sigurnosti ponovljenih doza u štakora, ehokardiografijom nisu utvrđeni znakovi dekompenzacije srca pri sistemskoj izloženosti 1,4 puta većoj od one koja se postiže tijekom liječenja.
Wessling Hungary Kft. Anomymus u 6
Wessling Hungary Kft.
If you forget to take Posaconazole AHCL
Ako ste zaboravili uzeti Posakonazol AHCL
INFORMATION IN BRAILLE Posaconazole AHCL
PODACI NA BRAILLEOVOM PISMU Posakonazol AHCL
Accord Healthcare Limited Sage House, 319 Pinner Road North Harrow, Middlesex, HA1 4HF United Kingdom
North Harrow, Middlesex, HA1 4HF Ujedinjeno Kraljevstvo
LIST OF EXCIPIENTS Contains glucose.
Sadrži glukozu.
If you are not sure, talk to your doctor or pharmacist before taking Posaconazole AHCL.
Ako niste sigurni, obratite se svom liječniku ili ljekarniku prije nego počnete uzimati Posakonazol AHCL.
Common: the following may affect up to 1 in 10 people - a change in the salt level in your blood shown in blood tests - signs include feeling confused or weak - abnormal skin sensations, such as numbness, tingling, itching, creeping, pricking or burning - headache - low potassium levels - shown up in blood tests - low magnesium levels - shown up in blood tests - high blood pressure - loss of appetite, stomach pain or upset stomach, passing wind, dry mouth, changes in your taste - heartburn (a burning sensation in the chest rising up to the throat) - low levels of “neutrophils” a type of white blood cell (neutropenia) -this can make you more likely to get infections and be shown up in blood tests - fever - feeling weak, dizzy, tired or sleepy - rash - itching - constipation - rectal discomfort
Često: mogu se javiti u do 1 na 10 osoba - poremećaj razine soli u krvi što se vidi na krvnim pretragama - znakovi uključuju osjećaj smetenosti ili slabosti - neuobičajeni kožni osjeti, kao što su utrnulost, trnci, svrbež, žmarci, bockanje ili žarenje - glavobolja - niske razine kalija - vide se na krvnim pretragama - niske razine magnezija - vide se na krvnim pretragama - povišen krvni tlak - gubitak apetita, bol u želucu ili nadražen želudac, vjetrovi, suha usta, promjene osjeta okusa - žgaravica (žarenje u prsnom košu koje se diže do grla) - niske razine neutrofila, jedne vrste bijelih krvnih stanica (neutropenija) - zbog toga možete bili skloniji infekcijama i to se može vidjeti na krvnim pretragama
It is, therefore, suggested to closely monitor for breakthrough fungal infections in patients weighing more than 120 kg.
Stoga se predlaže poman nadzor bolesnika tjelesne težine veće od 120 kg zbog mogućih probojnih gljivičnih infekcija.
Treatment of azole-susceptible Oropharyngeal Candidiasis (OPC) A randomised, evaluator-blind, controlled study was completed in HIV-infected patients with azolesusceptible oropharyngeal candidiasis (most patients studied had C. albicans isolated at baseline).
Provedeno je randomizirano kontrolirano ispitivanje u bolesnika zaraženih HIV-om s kandidijazom usta i ždrijela osjetljivom na azole (u većine je bolesnika na početku ispitivanja izolirana C. albicans),
Posaconazole AHCL should be administered with caution to patients with pro-arrhythmic conditions such as: - Congenital or acquired QTc prolongation - Cardiomyopathy, especially in the presence of cardiac failure - Sinus bradycardia - Existing symptomatic arrhythmias - Concomitant use with medicinal products known to prolong the QTc interval (other than those mentioned in section 4.3).
urođeno ili stečeno produljenje QTc-intervala kardiomiopatija, osobito ako je prisutno zatajenje srca sinusna bradikardija postojeće simptomatske aritmije istodobna primjena lijekova za koje je poznato da produljuju QTc-interval (osim lijekova navedenih u dijelu 4.3).
NAME OF THE MEDICINAL PRODUCT Posaconazole AHCL 40 mg/mL oral suspension
NAZIV LIJEKA Posakonazol AHCL 40 mg/ml oralna suspenzija
Certain medicines may increase the risk of side effects of Posaconazole AHCL by increasing the amount of Posaconazole AHCL in the blood.
Neki lijekovi mogu povećati rizik od nuspojava lijeka Posakonazol AHCL jer povećavaju njegovu količinu u krvi.
Titanium dioxide (E171)
glukoza, tekuća glicerol (E422) titanijev dioksid (E171) aroma jagode (sadrži propilenglikol)
Posaconazole oral suspension
Sažetak ispitivanja posakonazol oralne suspenzije
If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before taking Posaconazole AHCL.
Ako se nešto od gore navedenog odnosi na Vas (ili niste sigurni), obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete Posakonazol AHCL.
Study 316 was a randomised, double-blind trial of posaconazole oral suspension (200 mg three times a day) versus fluconazole capsules (400 mg once daily) in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease (GVHD).
Ispitivanje 316 bilo je randomizirano, dvostruko slijepo ispitivanje primjene posakonazol oralne suspenzije (200 mg triput na dan) naspram flukonazol kapsula (400 mg jedanput na dan) u primatelja alogeničnih hematopoetskih matičnih stanica koji su imali reakciju presatka protiv primatelja (engl.